A Great Scientific Achievement
Canada Royal Enoch Phytomedicine Ltd. selects high-quality Araliaceae
ginseng species (Asian ginseng, American ginseng, panax notoginseng, etc.) and
transforms
them into 16 rare ginsenosides, namely Rk2, Rg3(S, R), Rh2(S, R), Rg5, Rk1, Rk3, Rh1(S,
R),
Rh3, Rh4, aPPT(S, R), aPPD(S, R), on a large scale with propriety technology. These
sixteen
rare ginsenosides are further prepared and formulated to Redsenol capsules. Eight highly
active rare ginsenosides are meticulously selected to formulate Redsenol-DAG sublingual
pills.
Redsenol meets U.S. Pharmacopeial Convention (USP), each capsule has gone
through 70 strict screenings by Labs-Mart Inc. located in Canada (i.e. 5 heavy metal
contaminants screenings, 5 microbial contaminants screenings, 60 pesticide residue screenings).
Redsenol Rare Ginsenosides capsule is confirmed to be safe and effective, suitable for long-term
use.
Development Timelines
2005
Began to produce highly-purified rare ginsenosides Rg3, Rh2, Rh1, aPPD and aPPT etc., in large scale, at the same time, successfully developed natural plant skin care products with anti-oxidant, anti-aging, and skin-tone-evening properties. These products were sold in beauty salons.
2009
Developed the rare ginsenoside aglycone protopanaxadiol (aPPD) micro packaging soft gelatin capsules.
2010
Achieved a break-through in our proprietary technology production of the highly purified aglycone protopanaxadiol (aPPD) and the aglycone proto- panaxatriol (aPPT) by oxidation catalysis.
2011
Developed an industrialized production technology in transforming protopanaxadiol to rare ginsenosides Rk1, Rg5, Rk2, Rh3, at the same time, successfully developed water-soluble and lipid-soluble gelatin capsules.
2012
North American and European users began to take the Redsenol-1 Noble Ginsenosides capsules.
2013-2015
Tested rare ginsenosides' effects through in vitro cell experiments, and obtained confirming results on their broad-spectrum activity.
2016
Worked on the market promotion of the Redsenol-1 Noble Ginsenosides capsules.
2017
Meticulously selected eight highly active rare ginsenosides for the preparation of Redsenol-DAG sublingual pills.
2005
Began to produce highly-purified rare ginsenosides Rg3, Rh2, Rh1, aPPD and aPPT etc., in large scale, at the same time, successfully developed natural plant skin care products with anti-oxidant, anti-aging, and skin-tone-evening properties. These products were sold in beauty salons.
2009
Developed the rare ginsenoside aglycone protopanaxadiol (aPPD) micro packaging soft gelatin capsules.
2010
Achieved a break-through in our proprietary technology production of the highly purified aglycone protopanaxadiol (aPPD) and the aglycone proto- panaxatriol (aPPT) by oxidation catalysis.
2011
Developed an industrialized production technology in transforming protopanaxadiol to rare ginsenosides Rk1, Rg5, Rk2, Rh3, at the same time, successfully developed water-soluble and lipid-soluble gelatin capsules.
2012
North American and European users began to take the Redsenol-1 Noble Ginsenosides capsules.
2013-2015
Tested rare ginsenosides' effects through in vitro cell experiments, and obtained confirming results on their broad-spectrum activity.
2016
Worked on the market promotion of the Redsenol-1 Noble Ginsenosides capsules.
2017
Meticulously selected eight highly active rare ginsenosides for the preparation of Redsenol-DAG sublingual pills.
2022
Canada Royal Enoch announced the launch of a new clinical trial to examine the efficacy of Redsenol-1 Plus Noble Ginsenoside Capsules, for treating cancer-related fatigue.